Evaluation of the frequency and intensity of COVID-19 in patients with ankylosing spondylitis under anti-TNF therapy

Sümeyye Merve TÜRK¹,*, Zeynep ÖZTÜRK¹, Damla KARATAŞ¹, Ünal ERKORKMAZ², Emel GÖNÜLLÜ¹

¹ Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Sakarya University, Sakarya, Turkey
² Department of Bioistatistics, Faculty of Medicine, Sakarya University, Sakarya, Turkey

Correspondence: Sümeyye Merve TÜRK e-mail: sumeyyeaygan@yahoo.com.tr

Sümeyye Merve TÜRK https://orcid.org/0000-0003-0662-4837
Zeynep ÖZTÜRK https://orcid.org/0000-0001-6439-000X
Damla KARATAŞ https://orcid.org/0000-0002-4755-0443
Ünal ERKORKMAZ https://orcid.org/0000-0002-8497-4704
Emel GÖNÜLLÜ https://orcid.org/0000-0002-6990-4206
Dear Editor,

After the coronavirus disease 2019 (COVID-19) pandemic affected the whole world, rheumatologists began to think about how COVID-19 will progress in patients with inflammatory conditions. High cytokine levels play a role in the pathophysiology of COVID-19 infection.

Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine known to have a key role in the pathogenesis of chronic immune-mediated diseases. Anti-TNF therapy may cause increase in active tuberculosis, other granulomatous diseases and serious infections [1]. According to many studies, rheumatological diseases have not been identified as a risk factor for severe COVID-19 infection [2]. Should significantly increased cytokine levels during COVID-19 infection make us think about anti-cytokine therapies that may be used in the treatment of patients with COVID-19 rather than a risk?

We aimed to explore whether the frequency of COVID-19 infection increased, the effect of comorbidities on the frequency of infection, whether the severity of the disease and need for intensive care support increased in patients who used anti-TNF agents. We performed a retrospective case-control study between March and December 2020 in Sakarya University Training and Research Hospital. Retrospectively, we evaluated whether there was a difference in the frequency and severity of COVID-19 in our patients diagnosed with ankylosing spondylitis (AS), 77 of whom were using anti-TNF and 49 of whom didn’t use anti-TNF. Hospitalization and intensive care unit (ICU) requirements were evaluated as endpoints. In the anti-TNF group, patients used adalimumab, etanercept, certolizumab, infliximab and golimumab. Patients were questioned at outpatient clinic visits or by phone.
77 patients with AS using anti-TNF agents (58 males, 19 females) and 49 patients with AS (38 males, 11 females) not using anti-TNF agents were included in the study (p=0.943). Mean age of patients using anti-TNF agents was 41.53±10.38 and mean age of patients not using anti-TNF agents was 42.94±10.86 (p=0.468). 33 (42.9%) patients smoked in the anti-TNF group and 23 (46.9%) patients smoked without using TNFi (p=0.791). There was 12 pack-year smoking in the anti-TNF group, and 14 pack-year smoking in not using TNFi (p=0.623). The frequency of diabetes mellitus (DM), Hypertension (HT), Amiloidosis, Familial Mediterranean Fever (FMF), Coronary Artery Disease (CAD), Chronic Obstructive Pulmonary Disease (COPD) was similar in both groups (p=0.403, p=0.999, p=0.521, p=0.999, p=0.999, respectively). 6 patients using TNFi and 3 patients not using recovered from COVID-19 infection. However, this result was not statistically significant (p =0.999). One patient using anti-TNF was hospitalized but no need for admission to the ICU (p = 0.999). All 9 patients recovering from COVID-19 were male (p=0.113). There were 2 (22.2%) smokers in the SARS-CoV-2 positive group and 54 (46.2%) smokers in SARS-CoV-2 negative group (p=0.297). There was 37.5 pack year smoking in SARS-CoV-2 positive group, and 12 pack year smoking in SARS-CoV-2 negative group (p=0.151). Nobody has comorbidities (DM, HT, Amiloidosis, FMF, CAD, COPD) in SARS-CoV-2 positive group. There were patients with DM (5.1%), HT (15.4%), Amiloidosis (1.7%), FMF (1.7%), CAD (0.9%) and COPD (0.9%) in SARS-CoV-2 negative group (p=0.999, p=0.356, p=0.999, p=0.999, p=0.999, p=0.999, respectively). Having comorbidities was not detected to be associated with frequency of COVID-19. 31 (40.3%) patients adalimumab, 25 (32.5%) patients etanercept, 13 patients (16.9%) certolizumab, 6 (7.8%) patients golimumab and 2 patients (2.6%) was using infliximab in TNF group. 6 patients using anti-TNF (2 adalimumab, 1
etanercept, 1 golimumab, 2 infliximab) and 3 patients of non-user recovered from COVID-19 (p=0.999). No statistically significant difference was found between SARS-CoV-2 positive and negative patients in terms of the types of anti-TNF they used.

Patients were called in March 2020, when the COVID-19 pandemic began, and they were advised to discontinue their anti-TNF therapy. Among those who used anti-TNF, 2 (33.3%) people who had COVID-19 and 38 (53.5%) people who did not have COVID-19 interrupted treatment (p=0.419). Anti-TNF users who did not have COVID-19 interrupted treatment for an average of 3 months (min 2-max 4 months) starting from March 2020, and 1.5 months (min 1-max 2 months) who had COVID-19 (p=0.102). Duration of interrupting TNFi was not significant for the risk of COVID-19.

Comorbidities, older age, and the presence of active disease have been associated with worse outcomes in previous studies [3]. In our study, the group using anti-TNF and non-user group were similar according to age, gender and comorbidities. Although comorbidities in COVID-19 are associated with severe disease in the literature, we did not find a significant difference in our study. This result is probably related to our insufficient number of patients. As a result, we found that the use of anti-TNF did not increase the frequency and severity of COVID-19. In a recently published multicenter study, it was stated that the use of biological DMARDs in patients with inflammatory rheumatic diseases were not significantly associated with a worse outcome of COVID-19. But unlike our study, having no comorbidities was associated with a decreased risk of a worse outcome [4].

There are currently studies investigating the therapeutic utility of infliximab and adalimumab in hospitalized COVID-19 patients [5]. The results of these studies are very
important. The usability of TNFi in treatment and at which stage of the disease anti-TNF agents can be used are wondered. We will see the course of the disease all over the world after the administration of the COVID-19 vaccines, but we still need more information about effective and safe treatment.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**Financial disclosure**

The authors have no sources of support for this work.
References


